Evidence map›Paper›PMID 39883140›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management.

Wei Guo, Weizhi Xu, Tinghua Meng, Chunlei Fan, Hao Fu, Yizhen Pang, Liang Zhao, Long Sun, Jingxiong Huang, Yanjun Mi and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Prospective comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Comparison between [EJNMMI research · 2026
    Article
  6. Review
  7. Article
  8. Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wei Guo *Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Weizhi Xu *Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Tinghua Meng *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Chunlei Fan *Department of Colorectal Tumor Surgery, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Hao FuDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yizhen PangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Liang ZhaoDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Long SunDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jingxiong HuangDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. hjx9@126.com.
Yanjun MiDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. Miyj77@xmu.edu.cn.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. 71lu@163.com.
Haojun ChenDepartment of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. leochen0821@foxmail.com.ORCID 0000-0002-9101-8884

Funding

Fujian Natural Science Foundation for Distinguished Yong Scholars 2022D005Fujian Research and Training Grants for Young and China Fujian Research and Training Grants for Young and ChinaKey Scientific Research Program for Yong Scholars in Fujian 2021ZQNZD016National Natural Science Foundation of China 82422039
6 · The paper itself

Abstract

purposeTo evaluate the diagnostic accuracy and clinical impact of fibroblast activation protein (FAP)-targeted PET/CT imaging in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [

methodsWe prospectively analyzed patients with diagnosed or suspected breast cancer who underwent concomitant FAP-targeted PET/CT (radiotracers including either [

resultsSixty-one female patients (median age, 52 y; range, 28-82 y) were included. Among them, 23 patients underwent evaluation for a definitive diagnosis of suspected breast lesions, 15 underwent initial staging, and 23 were evaluated for the detection of recurrence. The sensitivities of breast US, [

conclusionFAP-targeted PET/CT was superior to [

Indexed as

Breast NeoplasmsGelatinasesMembrane ProteinsPositron Emission Tomography Computed TomographySerine EndopeptidasesAdultAgedAged, 80 and overEndopeptidasesFemaleFibroblast Activation Protein AlphaFluorodeoxyglucose F18HumansMiddle AgedProspective StudiesEndopeptidasesFibroblast Activation Protein AlphaFluorodeoxyglucose F18GelatinasesMembrane ProteinsSerine Endopeptidases[18F]FDGBreast cancerCancer managementFibroblast activation proteinTNM staging

Identifiers

PMID39883140

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.